14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $14.58 $20.11 Thursday, 2nd May 2024 DNLI stock ended at $16.81. This is 4.02% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 6.41% from a day low at $15.92 to a day high of $16.94.
90 days $14.58 $23.52
52 weeks $14.58 $33.31

Historical Denali Therapeutics Inc. prices

Date Open High Low Close Volume
Jan 16, 2024 $18.20 $18.62 $18.00 $18.37 689 825
Jan 12, 2024 $18.96 $19.20 $18.23 $18.54 877 583
Jan 11, 2024 $18.53 $18.95 $18.45 $18.69 1 339 148
Jan 10, 2024 $19.51 $19.76 $18.56 $18.79 1 155 393
Jan 09, 2024 $20.00 $20.07 $19.55 $19.74 703 504
Jan 08, 2024 $19.26 $20.36 $18.79 $20.36 903 942
Jan 05, 2024 $19.77 $19.90 $19.13 $19.34 1 216 563
Jan 04, 2024 $20.48 $20.50 $20.02 $20.27 649 842
Jan 03, 2024 $20.94 $20.94 $20.18 $20.33 909 902
Jan 02, 2024 $21.12 $21.93 $20.55 $21.39 662 742
Dec 29, 2023 $21.91 $21.91 $21.43 $21.46 726 520
Dec 28, 2023 $22.13 $22.37 $21.60 $21.95 831 236
Dec 27, 2023 $22.45 $22.62 $21.88 $22.21 715 209
Dec 26, 2023 $22.39 $22.98 $22.31 $22.35 627 537
Dec 22, 2023 $21.87 $22.61 $21.56 $21.96 745 698
Dec 21, 2023 $21.69 $21.81 $21.01 $21.56 1 155 759
Dec 20, 2023 $22.65 $22.72 $21.12 $21.17 1 230 009
Dec 19, 2023 $22.21 $22.95 $22.02 $22.65 1 136 430
Dec 18, 2023 $22.94 $23.03 $21.75 $21.78 925 301
Dec 15, 2023 $23.39 $23.81 $22.43 $22.94 3 028 468
Dec 14, 2023 $22.23 $23.60 $22.00 $23.18 1 920 384
Dec 13, 2023 $19.85 $21.59 $19.54 $21.55 1 486 838
Dec 12, 2023 $18.27 $19.63 $17.87 $19.29 921 905
Dec 11, 2023 $18.30 $18.75 $17.91 $18.24 1 660 127
Dec 08, 2023 $18.70 $18.72 $18.05 $18.37 800 410
Click to get the best stock tips daily for free!

About Denali Therapeutics Inc.

Denali Therapeutics. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for ... DNLI Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT